{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:59:34Z","timestamp":1780945174498,"version":"3.54.1"},"reference-count":32,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2015Z\u00d709102016"],"award-info":[{"award-number":["2015Z\u00d709102016"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2679784","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:27:39Z","timestamp":1780943259000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Development of a pandemic H5N1 influenza vaccine using MDCK suspension cells: A scalable and efficient production platform"],"prefix":"10.1080","volume":"22","author":[{"given":"Shaobo","family":"Zhang","sequence":"first","affiliation":[{"name":"Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihao","family":"Wang","sequence":"additional","affiliation":[{"name":"Lanzhou Bailing Biotechnology Co., Ltd","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwu","family":"Jin","sequence":"additional","affiliation":[{"name":"Lanzhou Bailing Biotechnology Co., Ltd","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., LTD","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongren","family":"Ma","sequence":"additional","affiliation":[{"name":"Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Yang","sequence":"additional","affiliation":[{"name":"Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2"},{"key":"e_1_3_3_3_1","unstructured":"World Health Organization (WHO). Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO 2003-2022. 2023. Geneva Switzerland: World Health Organization."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.03.009"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105632"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30346-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6020019"},{"key":"e_1_3_3_8_1","first-page":"1910","article-title":"65 years of influenza vaccine development: a continuing story","volume":"38","author":"Ziegler T","year":"2020","unstructured":"Ziegler T, Mamahit A, Cox NJ. 65 years of influenza vaccine development: a continuing story. Vaccine. 2020;38:1910\u20131917.","journal-title":"Vaccine"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181999"},{"issue":"1","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virol.2007.07.002","article-title":"Enhanced growth of seed viruses for H5N1 influenza vaccines","volume":"366","author":"Horimoto T","year":"2007","unstructured":"Horimoto T, Murakami S, Muramoto Y, Yamada S, Fujii K, Kiso M, Iwatsuki-Horimoto K, Kino Y, Kawaoka Y. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology. 2007;366(1):23\u201327.","journal-title":"Virology"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834ac7a3"},{"key":"e_1_3_3_12_1","unstructured":"World Health Organization (WHO). Development and licensing of cell culture derived influenza vaccines. WHO Technical Report Series. 2012; 979."},{"key":"e_1_3_3_13_1","first-page":"1","article-title":"Cell culture-based vaccine production: technological advances and challenges","volume":"165","author":"Genzel Y","year":"2018","unstructured":"Genzel Y, Reichl U. Cell culture-based vaccine production: technological advances and challenges. Cell Culture Eng. 2018;165:1\u201322.","journal-title":"Cell Culture Eng"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17081097"},{"key":"e_1_3_3_15_1","first-page":"4328","article-title":"New avian suspension cell lines provide production of influenza virus in serum-free media","volume":"28","author":"Lohr V","year":"2010","unstructured":"Lohr V, Rath A, Genzel Y, Jordan, I., Sandig, V, Reichl, U. New avian suspension cell lines provide production of influenza virus in serum-free media. Vaccine. 2010;28:4328\u20134333.","journal-title":"Vaccine"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3128"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.021"},{"key":"e_1_3_3_18_1","first-page":"695","article-title":"Safety and immunogenicity of a cell culture-derived inactivated influenza vaccine: a phase 1\/2 randomized, observer-blind, placebo-controlled trial","volume":"17","author":"Barretto N","year":"2021","unstructured":"Barretto N, Pardi N, Brito LA, Momin N, Ku AT, Pardi M, Zhang S, LaBranche C, Smith L, Haynes BF. Safety and immunogenicity of a cell culture-derived inactivated influenza vaccine: a phase 1\/2 randomized, observer-blind, placebo-controlled trial. Hum Vaccin Immunother. 2021;17:695\u2013704.","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_3_19_1","first-page":"1241","article-title":"Safety and immunogenicity of a Madin-Darby canine kidney cell-based pandemic influenza A H7N9 vaccine: a phase 1 randomized clinical trial","volume":"221","author":"Ge J","year":"2020","unstructured":"Ge J, Wang X, Tao L, Wen Z, Li F, Zhang Y, Chen H, Liu S, Wang L, Zhou P. Safety and immunogenicity of a Madin-Darby canine kidney cell-based pandemic influenza A H7N9 vaccine: a phase 1 randomized clinical trial. J Infect Dis. 2020;221:1241\u20131249.","journal-title":"J Infect Dis"},{"issue":"11","key":"e_1_3_3_20_1","first-page":"981","article-title":"Establishment of a new MDCK suspension cell line and its sensitivity study on influenza virus","volume":"35","author":"Li ZL","year":"2019","unstructured":"Li ZL, Wang JM, Zhao CH, Wang, MH, Li, L, Zhang, XM, Li, Z, Jin, DW, Ma, ZR, Qiao, ZL. Establishment of a new MDCK suspension cell line and its sensitivity study on influenza virus. Chin J Zoonoses. 2019;35(11):981\u2013988.","journal-title":"Chin J Zoonoses"},{"issue":"11","key":"e_1_3_3_21_1","first-page":"1362","article-title":"Establishment of MDCK suspension cell line in serum-free medium at high cell density in bioreactors","volume":"34","author":"Zhao CH","year":"2021","unstructured":"Zhao CH, Wang MH, Li ZL, Jin DW, Ma H, Ma ZR, Qiao ZL, Chen H, Zhang JY, Wang JM. Establishment of MDCK suspension cell line in serum-free medium at high cell density in bioreactors. Chin J Biologicals. 2021;34(11):1362\u20131368.","journal-title":"Chin J Biologicals"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055778"},{"key":"e_1_3_3_23_1","volume-title":"Guideline on the quality of biological active substances produced by stable transgene expression in higher plants","author":"European Medicines Agency (EMA)","year":"2008","unstructured":"European Medicines Agency (EMA). Guideline on the quality of biological active substances produced by stable transgene expression in higher plants. London, UK: European Medicines Agency (EMA); 2008."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.054"},{"key":"e_1_3_3_25_1","unstructured":"China National Biotec Group (CNBG). Yang XM team\u2019s latest achievement: China\u2019s first cell-based quadrivalent influenza vaccine enters phase III clinical trial. China Pharmaceutical Innovation Association. Beijing China: China Pharmaceutical Innovation Association; 2023."},{"issue":"5","key":"e_1_3_3_26_1","first-page":"587","article-title":"Production of inactivated influenza H5N1 vaccines from MDCK cells in serum\u2011free medium","volume":"15","author":"Hu AY","year":"2008","unstructured":"Hu AY, Tseng, YF, Weng, TC, Liao, C.C., Wu, J, Chou, AH, Chao, HJ, Gu, A, Chen, J, Lin, SC et al. Production of inactivated influenza H5N1 vaccines from MDCK cells in serum\u2011free medium. J Biomed Sci. 2008;15(5):587\u2013595.","journal-title":"J Biomed Sci"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-11050-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.4472-4477.1998"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.128"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14091937"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2012.08.002"},{"key":"e_1_3_3_32_1","unstructured":"National Advisory Committee on Immunization (NACI). Preliminary guidance on human vaccination against avian influenza in a non-pandemic context. Canada Communicable Disease Report. Ottawa ON: Public Health Agency of Canada; 2025."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2024.11.005"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2679784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:27:42Z","timestamp":1780943262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2679784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2679784"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2679784","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2679784"}}